Dow Jones

39,118.86

-0.12%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

CMPS

COMPASS Pathways (CMPS)

COMPASS Pathways PLC

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CMPS

1 2 3 4 5 6 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
26/06/2024	05:30	GlobeNewswire Inc.	Compass Pathways appoints Lori Englebert as Chief Commercial Officer	NASDAQ:CMPS	COMPASS Pathways PLC
22/05/2024	15:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CMPS	COMPASS Pathways PLC
09/05/2024	16:28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CMPS	COMPASS Pathways PLC
08/05/2024	05:45	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CMPS	COMPASS Pathways PLC
08/05/2024	05:45	GlobeNewswire Inc.	Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights	NASDAQ:CMPS	COMPASS Pathways PLC
08/05/2024	05:30	GlobeNewswire Inc.	Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder	NASDAQ:CMPS	COMPASS Pathways PLC
02/05/2024	05:30	GlobeNewswire Inc.	Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment	NASDAQ:CMPS	COMPASS Pathways PLC
29/04/2024	05:30	GlobeNewswire Inc.	Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression	NASDAQ:CMPS	COMPASS Pathways PLC
28/03/2024	07:00	GlobeNewswire Inc.	Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors	NASDAQ:CMPS	COMPASS Pathways PLC
05/03/2024	16:05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CMPS	COMPASS Pathways PLC
29/02/2024	06:00	GlobeNewswire Inc.	Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights	NASDAQ:CMPS	COMPASS Pathways PLC
29/02/2024	05:59	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:CMPS	COMPASS Pathways PLC
14/02/2024	15:08	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CMPS	COMPASS Pathways PLC
16/01/2024	07:00	GlobeNewswire Inc.	Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved	NASDAQ:CMPS	COMPASS Pathways PLC
05/01/2024	16:04	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CMPS	COMPASS Pathways PLC
05/01/2024	07:00	GlobeNewswire Inc.	Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement	NASDAQ:CMPS	COMPASS Pathways PLC
02/01/2024	16:20	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:CMPS	COMPASS Pathways PLC
19/12/2023	15:05	GlobeNewswire Inc.	Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder	NASDAQ:CMPS	COMPASS Pathways PLC
13/12/2023	16:40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:CMPS	COMPASS Pathways PLC
07/12/2023	06:00	GlobeNewswire Inc.	Compass Pathways appoints Teri Loxam as Chief Financial Officer	NASDAQ:CMPS	COMPASS Pathways PLC
06/12/2023	15:00	GlobeNewswire Inc.	Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry	NASDAQ:CMPS	COMPASS Pathways PLC
15/11/2023	03:00	GlobeNewswire Inc.	Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center	NASDAQ:CMPS	COMPASS Pathways PLC
02/11/2023	06:00	GlobeNewswire Inc.	COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights	NASDAQ:CMPS	COMPASS Pathways PLC
26/10/2023	07:00	GlobeNewswire Inc.	COMPASS Pathways announces CFO transition	NASDAQ:CMPS	COMPASS Pathways PLC
19/09/2023	08:14	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:CMPS	COMPASS Pathways PLC
18/09/2023	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CMPS	COMPASS Pathways PLC
18/09/2023	15:31	GlobeNewswire Inc.	COMPASS Pathways appoints Daphne Karydas to its Board of Directors	NASDAQ:CMPS	COMPASS Pathways PLC
08/09/2023	16:17	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:CMPS	COMPASS Pathways PLC
06/09/2023	03:00	GlobeNewswire Inc.	COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression	NASDAQ:CMPS	COMPASS Pathways PLC
24/08/2023	19:51	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:CMPS	COMPASS Pathways PLC